Navigation Links
VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
Date:4/23/2013

SEATTLE, April 23, 2013 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. today announced the appointment of James Kyle Bryan , M.D. as Chief Medical Officer.  A hematologist and medical oncologist, Dr. Bryan brings more than 20 years of oncology drug discovery and development experience in the pharmaceutical and biotechnology industry to VentiRx.  This includes extensive operational and strategic leadership work in his previous roles as Vice President of Global Product Development at PPD, Inc., a global contract research organization, and as Vice President of Medical Affairs at Seattle Genetics.

(Logo:  http://photos.prnewswire.com/prnh/20120828/SF63676LOGO)

"Kyle will be integral in directing our clinical development efforts, which will  include our ongoing randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with pegylated liposomal doxorubicin in patients with recurrent or persistent ovarian cancer and our upcoming Phase 2 trial of VTX-2337 in head and neck cancer patients," said Robert Hershberg , M.D., Ph.D., Chief Executive Officer of VentiRx. "His extensive experience in oncology drug development combined with his strong connections to oncology thought leaders will be invaluable to VentiRx going forward.  We are delighted to have him join the VentiRx team."

Board-certified in medical oncology, hematology and internal medicine, Dr. Bryan currently serves on the clinical faculty of medicine for hematology and oncology at the University of Washington Medical Center.  Dr. Bryan received a B.S. in biochemistry and an M.D. from Louisiana State University and completed his fellowship in hematology and oncology at the University of Washington.

About VentiRx Pharmaceuticals
VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases.  The Company's lead product candidate is VTX-2337, a small molecule TLR8 agonist for the treatment of cancer. VentiRx has an exclusive, world-wide collaboration with Celgene Corporation for VTX-2337. VentiRx is a privately held organization based in Seattle, Washington.  For additional information, please visit www.ventirx.com.

 


'/>"/>
SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
2. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
3. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
4. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
5. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
6. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
7. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
8. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
9. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
10. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
11. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
Breaking Biology Technology:
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):